Alpha Modus (AMOD) Chief Executive William Alessi emphasized Thursday the company's "strong" fundamentals and an "ongoing" growth strategy amid "uninformed speculation" by certain market participants.
"The recent sell-side activity targeting AMOD stock appears to be driven by misconceptions and a lack of understanding about our business and long-term strategy coupled with the 'de-SPAC norm,'" Alessi said in a company statement.
Shares soared 133% as intraday trading volume surged to over 115.9 million from a daily average of about 66,000.
Tectonic Therapeutic (TECX) shares surged 109% after the company said Thursday a phase 1b trial showed that a single intravenous dose of TX45 resulted in "meaningful improvements" in left ventricular function and pulmonary hemodynamics.
Over 4.3 million shares traded intraday versus a daily average of nearly 144,000.
Alterity Therapeutics (ATHE) said Thursday its ATH434 lead candidate demonstrated 48% slowing of clinical progression in a phase 2 clinical trial in patients with early-stage multiple system atrophy.
Shares jumped 50% as intraday trading volume catapulted to more than 20.6 million from a daily average of about 71,000.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.